Video

Dr. Freedland on Real-World Utility of Enzalutamide in Prostate Cancer

Author(s):

Stephen J. Freedland, MD

In Partnership With:

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer; director of the Center for Integrated Research in Cancer and Lifestyle; co-director of the Cancer Genetics and Prevention Program; associate director of the Faculty Development Samuel Oschin Comprehensive Cancer Institute; and professor of surgery at Cedars-Sinai, discusses remaining questions with the real-world utility of enzalutamide (Xtandi) in prostate cancer.

Data from multiple phase 3 trials have demonstrated that enzalutamide is a novel therapy for prostate cancer, specifically in the metastatic castration-sensitive, nonmetastatic, and metastatic castration-resistant settings, says Freedland. Clinical trial data have shown that the agent surprises androgen signaling, reduces prostate-specific antigen, and slows tumor growth, which improves overall survival for patients, explains Freedland.

However, how this agent will be utilized in the real-world settingremains an open question. The trials that have examined the agent thus far are highly selective; they accrue healthy patients who adhere to the medicine and get their blood tests done on time, says Freedland. The question of whether similar efficacy will be seen in the real world with regard to PSA control and time to progression remains open, concludes Freedland.

Related Videos
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Janaki Neela Sharma, MD
Matthew Powell, MD
Noman Ashraf, MD
Sheldon M. Feldman, MD
Related Content
Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles
October 8th 2024

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

Stephen J. Freedland, MD
May 4th 2024

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Loss of Y Chromosome in Men Enables Cancer to Grow
July 18th 2023

Loss of Y Chromosome in Men Enables Cancer to Grow

Yuan Yuan, MD, PhD
June 27th 2023

Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC